利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

39 条记录 (耗时 0.044 秒)

    C5-SPIRO IMINOTHIAZINE DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE
    3.
    发明申请
    C5-SPIRO IMINOTHIAZINE DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE 有权
    C5-SPIRO三嗪类二氧化物作为BACE抑制剂，组合物及其使用

    公开(公告)号：US20160222032A1

    公开(公告)日：2016-08-04

    申请号：US15021011

    申请日：2014-09-08

    申请人： Jack D. SCOTT ,  Wen-Lian WU ,  Jared N. CUMMING ,  MERCK SHARP & DOHME CORP.

    发明人： Jack D. Scott ,  Wen-Lian Wu ,  Jared N. Cumming

    IPC分类号： C07D513/10 ,  A61K45/06 ,  C07D417/12 ,  A61K31/547 ,  C07D519/00

    CPC分类号： C07D513/10 ,  A61K31/547 ,  A61K45/06 ,  C07D279/16 ,  C07D417/12 ,  C07D471/04 ,  C07D519/00 ,  A61K2300/00

    摘要： In its many embodiments, the present invention provides certain C5-spiro iminothiadiazine dioxide compounds, including compounds Formula (I): or a tautomers and/or stereoisomers thereof, and pharmaceutically acceptable salts of said compounds, said tautomers and said stereoisomers, wherein RL, X, Y, R1A, R1B, R2, R3, m, and RA are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.

    摘要翻译： 在其许多实施方案中，本发明提供某些C5-螺亚氨基二氮嗪二氧化物化合物，包括式（I）化合物：或其互变异构体和/或立体异构体，以及所述化合物，所述互变异构体和所述立体异构体的药学上可接受的盐，其中RL， X，Y，R 1A，R 1B，R 2，R 3，m和RA如本文所定义。 本发明的新化合物可用作BACE抑制剂和/或用于治疗和预防与其相关的各种病症。 还公开了包含一种或多种这样的化合物（单独和与一种或多种其它活性剂组合）的药物组合物及其制备和使用方法，包括用于治疗阿尔茨海默氏病的药物组合物。

    S-IMINO-S-OXO-IMINOTHIAZINE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE
    5.
    发明申请
    S-IMINO-S-OXO-IMINOTHIAZINE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE 有权
    S-IMINO-S-OXO-IMINOTHIAZINE化合物作为BACE抑制剂，组合物及其使用

    公开(公告)号：US20160016921A1

    公开(公告)日：2016-01-21

    申请号：US14774199

    申请日：2014-03-11

    申请人： Tanweer A. KHAN ,  Jack D. SCOTT ,  Jared N. CUMMING ,  MERCK SHARP & DOHME CORP.

    发明人： Tanweer A. Khan ,  Jack D. Scott ,  Jared N. Cumming

    IPC分类号： C07D279/12 ,  C07D417/12

    CPC分类号： C07D279/12 ,  C07D417/12

    摘要： In its many embodiments, the present invention provides certain S-imino-S-oxo iminothiazine compounds, including compounds Formula (I): or a tautomers and/or stereoisomers thereof, and pharmaceutically acceptable salts of said compounds, said tautomeros and said stereoisomers, wherein RN, R1A, R1B, R2, R3, R4, ring A, RA, m, L1-, and RL are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and may be useful for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.

    摘要翻译： 在其许多实施方案中，本发明提供某些S-亚氨基-S-氧亚氨基噻嗪化合物，包括式（I）化合物：或其互变异构体和/或立体异构体，以及所述化合物，所述互变异构体和所述立体异构体的药学上可接受的盐， 其中RN，R1A，R1B，R2，R3，R4，环A，RA，m，L1-和RL如本文所定义。 本发明的新化合物可用作BACE抑制剂，并且可用于治疗和预防与其相关的各种病症。 还公开了包含一种或多种这样的化合物（单独和与一种或多种其它活性剂组合）的药物组合物及其制备和使用方法，包括用于治疗阿尔茨海默氏病的药物组合物。

    DIARYL MORPHOLINES AS CB1 MODULATORS
    7.
    发明申请
    DIARYL MORPHOLINES AS CB1 MODULATORS 审中-公开
    二元醇作为CB1调节剂

    公开(公告)号：US20100197564A1

    公开(公告)日：2010-08-05

    申请号：US12593777

    申请日：2008-04-17

    申请人： Jack D. Scott ,  Andrew Stamford

    发明人： Jack D. Scott ,  Andrew Stamford

    IPC分类号： A61K31/5355 ,  C07D265/30 ,  A61K31/5375 ,  C07D413/12 ,  A61K38/28 ,  A61K31/397 ,  A61P3/00 ,  A61P3/04 ,  A61P3/06 ,  A61P25/00 ,  A61P29/00 ,  A61P1/00 ,  A61P9/00

    CPC分类号： C07D265/30 ,  C07D265/32 ,  C07D413/12

    摘要： The present invention provides compounds having the general structure of Formula (I) or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, which are useful as CB1 receptor antagonists. The compounds of the invention may be useful in treating diseases, disorders, or conditions responsive to CB1 receptor antagonists, including, but not limited to, metabolic syndrome, obesity, waist circumference, dyslipidemia, insulin sensitivity, neuroinflammatory disorders, cognitive disorders, psychosis, addictive behavior, gastrointestinal disorders, and cardiovascular conditions.

    摘要翻译： 本发明提供具有式（I）的通式结构的化合物或其药学上可接受的盐，溶剂合物，酯或前药，其可用作CB1受体拮抗剂。 本发明的化合物可用于治疗对CB1受体拮抗剂反应的疾病，病症或病症，包括但不限于代谢综合征，肥胖症，腰围，血脂异常，胰岛素敏感性，神经炎症性疾病，认知障碍，精神病， 成瘾行为，胃肠道疾病和心血管疾病。